User login
Do you currently treat patients with rare diseases? Do you suspect that you might have a patient with an undiagnosed rare disease? The National Organization for Rare Disorders (NORD) and the University of Massachusetts Medical School have designed two events for you and your colleagues to learn more about rare diseases and the available diagnostic tools.
An interactive half-day symposium on diagnostic hurdles, tools, and resources is planned for Sunday, October 16, 2017, at the Marriott Wardman Park Hotel in Washington DC. This event, “Finding a Zebra Among Many Horses,” will focus on challenges and resources related to rare disease diagnosis.
On the following two days, Oct. 16 and 17, NORD’s Rare Diseases and Orphan Products Breakthrough Summit will take place at the same location and is also CME-accredited. Topics to be covered will include:
- Assuring Patient Access: Future Outlook for Patient Assistance Programs
- The Challenge of Health Care Costs and Treatment Prices
- An Evergreen and Sustainable Approach to Orphan Drugs
- Next-Generation Treatments and Advancing Clinical Trials
The NORD Breakthrough Summit attracts approximately 600 participants from rare disease stakeholder groups, including clinicians, researchers, patient advocates, and government partners from the NIH and FDA.
Online registration is available now for either or both events.
Do you currently treat patients with rare diseases? Do you suspect that you might have a patient with an undiagnosed rare disease? The National Organization for Rare Disorders (NORD) and the University of Massachusetts Medical School have designed two events for you and your colleagues to learn more about rare diseases and the available diagnostic tools.
An interactive half-day symposium on diagnostic hurdles, tools, and resources is planned for Sunday, October 16, 2017, at the Marriott Wardman Park Hotel in Washington DC. This event, “Finding a Zebra Among Many Horses,” will focus on challenges and resources related to rare disease diagnosis.
On the following two days, Oct. 16 and 17, NORD’s Rare Diseases and Orphan Products Breakthrough Summit will take place at the same location and is also CME-accredited. Topics to be covered will include:
- Assuring Patient Access: Future Outlook for Patient Assistance Programs
- The Challenge of Health Care Costs and Treatment Prices
- An Evergreen and Sustainable Approach to Orphan Drugs
- Next-Generation Treatments and Advancing Clinical Trials
The NORD Breakthrough Summit attracts approximately 600 participants from rare disease stakeholder groups, including clinicians, researchers, patient advocates, and government partners from the NIH and FDA.
Online registration is available now for either or both events.
Do you currently treat patients with rare diseases? Do you suspect that you might have a patient with an undiagnosed rare disease? The National Organization for Rare Disorders (NORD) and the University of Massachusetts Medical School have designed two events for you and your colleagues to learn more about rare diseases and the available diagnostic tools.
An interactive half-day symposium on diagnostic hurdles, tools, and resources is planned for Sunday, October 16, 2017, at the Marriott Wardman Park Hotel in Washington DC. This event, “Finding a Zebra Among Many Horses,” will focus on challenges and resources related to rare disease diagnosis.
On the following two days, Oct. 16 and 17, NORD’s Rare Diseases and Orphan Products Breakthrough Summit will take place at the same location and is also CME-accredited. Topics to be covered will include:
- Assuring Patient Access: Future Outlook for Patient Assistance Programs
- The Challenge of Health Care Costs and Treatment Prices
- An Evergreen and Sustainable Approach to Orphan Drugs
- Next-Generation Treatments and Advancing Clinical Trials
The NORD Breakthrough Summit attracts approximately 600 participants from rare disease stakeholder groups, including clinicians, researchers, patient advocates, and government partners from the NIH and FDA.
Online registration is available now for either or both events.